Status:

COMPLETED

A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101

Lead Sponsor:

Alector Inc.

Conditions:

Healthy

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

Brief Summary

A first in human phase 1 study in healthy volunteers to assess AL101 safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics

Detailed Description

This is a first-in-human Phase 1 study designed to investigate the safety, tolerability, PK, PD and Bioavailability of intravenously and sub-cutaneously administered AL101 in Healthy Volunteers.

Eligibility Criteria

Inclusion

  • BMI 18.0-35.0 kg/m2
  • 45-120 kg, inclusive
  • At screening, females must be non-pregnant and non-lactating, or of nonchildbearing potential (either surgically sterilized or physiologically incapable of becoming pregnant, or at least 1-year postmenopausal (amenorrhoea duration of 12 consecutive months); nonpregnancy will be confirmed for all females by a pregnancy test conducted at screening, (each) admission, and at follow-up.
  • Female participants of child-bearing potential must agree to use adequate contraception from screening until 90 days after the follow-up visit.
  • In good physical health on the basis of no clinically significant findings from medical history, physical examination (PE), laboratory tests, 12 lead ECG, and vital signs, as judged by the Investigator.
  • Willingness and able to comply with the study protocol, in the investigator's judgement.

Exclusion

  • Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins.
  • Positive drug or alcohol at screening and prior to first dose
  • History of alcohol abuse or substance abuse

Key Trial Info

Start Date :

December 14 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 9 2022

Estimated Enrollment :

88 Patients enrolled

Trial Details

Trial ID

NCT04111666

Start Date

December 14 2019

End Date

June 9 2022

Last Update

August 10 2022

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Study site

Miami, Florida, United States, 33126

2

Study site

Orlando, Florida, United States, 32806